-
1
-
-
0345337254
-
Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program
-
McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol. 1998;16(8):2825-2833. (Pubitemid 28363048)
-
(1998)
Journal of Clinical Oncology
, vol.16
, Issue.8
, pp. 2825-2833
-
-
McLaughlin, P.1
Grillo-Lopez, A.J.2
Link, B.K.3
Levy, R.4
Czuczman, M.S.5
Williams, M.E.6
Heyman, M.R.7
Bence-Bruckler, I.8
White, C.A.9
Cabanillas, F.10
Jain, V.11
Ho, A.D.12
Lister, J.13
Wey, K.14
Shen, D.15
Dallaire, B.K.16
-
2
-
-
33644677932
-
New treatment options have changed the survival of patients with follicular lymphoma
-
DOI 10.1200/JCO.2005.03.1674
-
Fisher RI, LeBlanc M, Press OW, Maloney DG, Unger JM, Miller TP. New treatment options have changed the survival of patients with follicular lymphoma. J Clin Oncol. 2005;23(33):8447-8452. (Pubitemid 46260240)
-
(2005)
Journal of Clinical Oncology
, vol.23
, Issue.33
, pp. 8447-8452
-
-
Fisher, R.L.1
Leblanc, M.2
Press, O.W.3
Maloney, D.G.4
Unger, J.M.5
Miller, T.P.6
-
3
-
-
23044503407
-
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: A study by the groupe d'etude des lymphomes de l'adulte
-
DOI 10.1200/JCO.2005.09.131
-
Feugier P, Van Hoof A, Sebban C, et al. Longterm results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol. 2005;23(18):4117-4126. (Pubitemid 46211317)
-
(2005)
Journal of Clinical Oncology
, vol.23
, Issue.18
, pp. 4117-4126
-
-
Feugier, P.1
Van Hoof, A.2
Sebban, C.3
Solal-Celigny, P.4
Bouabdallah, R.5
Ferme, C.6
Christian, B.7
Lepage, E.8
Tilly, H.9
Morschhauser, F.10
Gaulard, P.11
Salles, G.12
Bosly, A.13
Gisselbrecht, C.14
Reyes, F.15
Coiffier, B.16
-
4
-
-
0642312825
-
Rituximab (monoclonal anti-CD20 antibody): Mechanisms of action and resistance
-
Smith MR. Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene. 2003;22(47):7359-7368.
-
(2003)
Oncogene
, vol.22
, Issue.47
, pp. 7359-7368
-
-
Smith, M.R.1
-
5
-
-
27244440161
-
Immunotherapy for non-Hodgkin's lymphoma: Monoclonal antibodies and vaccines
-
DOI 10.1200/JCO.2005.06.004
-
Maloney DG. Immunotherapy for non-Hodgkin's lymphoma: monoclonal antibodies and vaccines. J Clin Oncol. 2005;23(26):6421-6428. (Pubitemid 46218853)
-
(2005)
Journal of Clinical Oncology
, vol.23
, Issue.26
, pp. 6421-6428
-
-
Maloney, D.G.1
-
6
-
-
7244248664
-
From the bench to the bedside: Ways to improve rituximab efficacy
-
DOI 10.1182/blood-2004-03-1110
-
Cartron G, Watier H, Golay J, Solal-Celigny P. From the bench to the bedside: ways to improve rituximab efficacy. Blood. 2004;104(9):2635-2642. (Pubitemid 39434941)
-
(2004)
Blood
, vol.104
, Issue.9
, pp. 2635-2642
-
-
Cartron, G.1
Watier, H.2
Golay, J.3
Solal-Celigny, P.4
-
7
-
-
65549085367
-
Rituximab immunotherapy results in the induction of a lymphoma idiotype-specific T-cell response in patients with follicular lymphoma: Support for a "vaccinal effect" of rituximab
-
Hilchey SP, Hyrien O, Mosmann TR, et al. Rituximab immunotherapy results in the induction of a lymphoma idiotype-specific T-cell response in patients with follicular lymphoma: support for a "vaccinal effect" of rituximab. Blood. 2009;113(16):3809-3812.
-
(2009)
Blood
, vol.113
, Issue.16
, pp. 3809-3812
-
-
Hilchey, S.P.1
Hyrien, O.2
Mosmann, T.R.3
-
8
-
-
0036464719
-
Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammarIIIa gene
-
DOI 10.1182/blood.V99.3.754
-
Cartron G, Dacheux L, Salles G, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood. 2002;99(3):754-758. (Pubitemid 34525533)
-
(2002)
Blood
, vol.99
, Issue.3
, pp. 754-758
-
-
Cartron, G.1
Dacheux, L.2
Salles, G.3
Solal-Celigny, P.4
Bardos, P.5
Colombat, P.6
Watier, H.7
-
9
-
-
0642373290
-
Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma
-
DOI 10.1200/JCO.2003.05.013
-
Weng WK, Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol. 2003;21(21): 3940-3947. (Pubitemid 46606207)
-
(2003)
Journal of Clinical Oncology
, vol.21
, Issue.21
, pp. 3940-3947
-
-
Weng, W.-K.1
Levy, R.2
-
10
-
-
11144353984
-
Phase I Studies of Interleukin (IL)-2 and Rituximab in B-Cell Non-Hodgkin's Lymphoma: IL-2 Mediated Natural Killer Cell Expansion Correlations with Clinical Response
-
DOI 10.1158/1078-0432.CCR-1087-3
-
Gluck WL, Hurst D, Yuen A, et al. Phase I studies of interleukin (IL)-2 and rituximab in B-cell non-Hodgkin's lymphoma: IL-2 mediated natural killer cell expansion correlations with clinical response. Clin Cancer Res. 2004;10(7):2253-2264. (Pubitemid 38445682)
-
(2004)
Clinical Cancer Research
, vol.10
, Issue.7
, pp. 2253-2264
-
-
Gluck, W.L.1
Hurst, D.2
Yuen, A.3
Levine, A.M.4
Dayton, M.A.5
Gockerman, J.P.6
Lucas, J.7
Denis-Mize, K.8
Tong, B.9
Navis, D.10
Difrancesco, A.11
Milan, S.12
Wilson, S.E.13
Wolin, M.14
-
11
-
-
0036090166
-
Phase 1 study of interleukin-12 in combination with rituximab in patients with B-cell non-Hodgkin lymphoma
-
Ansell SM, Witzig TE, Kurtin PJ, et al. Phase 1 study of interleukin-12 in combination with rituximab in patients with B-cell non-Hodgkin lymphoma. Blood. 2002;99(1):67-74.
-
(2002)
Blood
, vol.99
, Issue.1
, pp. 67-74
-
-
Ansell, S.M.1
Witzig, T.E.2
Kurtin, P.J.3
-
12
-
-
45749104147
-
Granulocyte-macrophage colony-stimulating factor potentiates rituximab in patients with relapsed follicular lymphoma: Results of a phase II study
-
Cartron G, Zhao-Yang L, Baudard M, et al. Granulocyte-macrophage colony-stimulating factor potentiates rituximab in patients with relapsed follicular lymphoma: results of a phase II study. J Clin Oncol. 2008;26(16):2725-2731.
-
(2008)
J Clin Oncol
, vol.26
, Issue.16
, pp. 2725-2731
-
-
Cartron, G.1
Zhao-Yang, L.2
Baudard, M.3
-
13
-
-
0036554140
-
Interferonalpha as an immunotherapeutic protein
-
Brassard DL, Grace MJ, Bordens RW. Interferonalpha as an immunotherapeutic protein. J Leukoc Biol. 2002;71(4):565-581.
-
(2002)
J Leukoc Biol
, vol.71
, Issue.4
, pp. 565-581
-
-
Brassard, D.L.1
Grace, M.J.2
Bordens, R.W.3
-
14
-
-
36749069393
-
Interferons at age 50: Past, current and future impact on biomedicine
-
DOI 10.1038/nrd2422, PII NRD2422
-
Borden EC, Sen GC, Uze G, et al. Interferons at age 50: past, current and future impact on biomedicine. Nat Rev Drug Discov. 2007;6(12):975-990. (Pubitemid 350201788)
-
(2007)
Nature Reviews Drug Discovery
, vol.6
, Issue.12
, pp. 975-990
-
-
Borden, E.C.1
Sen, G.C.2
Uze, G.3
Silverman, R.H.4
Ransohoff, R.M.5
Foster, G.R.6
Stark, G.R.7
-
15
-
-
0032523158
-
Prolonged STAT1 activation related to the growth arrest of malignant lymphoma cells by interferon-alpha
-
Grimley PM, Fang H, Rui H, et al. Prolonged STAT1 activation related to the growth arrest of malignant lymphoma cells by interferon-alpha. Blood. 1998;91(8):3017-3027. (Pubitemid 28227555)
-
(1998)
Blood
, vol.91
, Issue.8
, pp. 3017-3027
-
-
Grimley, P.M.1
Fang, H.2
Rui, H.3
Petricoin III, E.F.4
Ray, S.5
Dong, F.6
Fields, K.H.7
Hu, R.8
Zoon, K.C.9
Audet, S.10
Beeler, J.11
-
16
-
-
0034536334
-
Cytochrome c release, mitochondrial membrane depolarization, caspase-3 activation, and Bax-alpha cleavage during IFN-alpha-induced apoptosis in Daudi B lymphoma cells
-
DOI 10.1089/107999000750053799
-
Yanase N, Ohshima K, Ikegami H, Mizuguchi J. Cytochrome c release, mitochondrial membrane depolarization, caspase-3 activation, and Baxalpha cleavage during IFN-alpha-induced apoptosis in Daudi B lymphoma cells. J Interferon Cytokine Res. 2000;20(12):1121-1129. (Pubitemid 32015252)
-
(2000)
Journal of Interferon and Cytokine Research
, vol.20
, Issue.12
, pp. 1121-1129
-
-
Yanase, N.1
Ohshima, K.2
Ikegami, H.3
Mizuguchi, J.4
-
17
-
-
0037790592
-
Apoptosis and interferons: Role of interferon-stimulated genes as mediators of apoptosis
-
DOI 10.1023/A:1023668705040
-
Chawla-Sarkar M, Lindner DJ, Liu YF, et al. Apoptosis and interferons: role of interferonstimulated genes as mediators of apoptosis. Apoptosis. 2003;8(3):237-249. (Pubitemid 36749609)
-
(2003)
Apoptosis
, vol.8
, Issue.3
, pp. 237-249
-
-
Chawla-Sarkar, M.1
Lindner, D.J.2
Liu, Y.-F.3
Williams, B.R.4
Sen, G.C.5
Silverman, R.H.6
Borden, E.C.7
-
18
-
-
0025673975
-
Effects of interferon alpha on autocrine growth factor loops in B lymphoproliferative disorders
-
Heslop HE, Bianchi AC, Cordingley FT, et al. Effects of interferon alpha on autocrine growth factor loops in B lymphoproliferative disorders. J Exp Med. 1990;172(6):1729-1734.
-
(1990)
J Exp Med
, vol.172
, Issue.6
, pp. 1729-1734
-
-
Heslop, H.E.1
Bianchi, A.C.2
Cordingley, F.T.3
-
19
-
-
0021933901
-
Close link between reduction of c-myc expression by interferon and, G0/G1 arrest
-
Einat M, Resnitzky D, Kimchi A. Close link between reduction of c-myc expression by interferon and, G0/G1 arrest. Nature. 1985;313(6003):597-600.
-
(1985)
Nature
, vol.313
, Issue.6003
, pp. 597-600
-
-
Einat, M.1
Resnitzky, D.2
Kimchi, A.3
-
20
-
-
0034672243
-
Interferon alpha down-regulates telomerase reverse transcriptase and telomerase activity in human malignant and nonmalignant hematopoietic cells
-
Xu D, Erickson S, Szeps M, et al. Interferon alpha down-regulates telomerase reverse transcriptase and telomerase activity in human malignant and nonmalignant hematopoietic cells. Blood. 2000;96(13):4313-4318.
-
(2000)
Blood
, vol.96
, Issue.13
, pp. 4313-4318
-
-
Xu, D.1
Erickson, S.2
Szeps, M.3
-
21
-
-
25844480780
-
Review: Milstein Award lecture: Interferons and cancer: Where from here?
-
Borden EC. Review: Milstein Award lecture: interferons and cancer: where from here? J Interferon Cytokine Res. 2005;25(9):511-527.
-
(2005)
J Interferon Cytokine Res
, vol.25
, Issue.9
, pp. 511-527
-
-
Borden, E.C.1
-
22
-
-
0033995976
-
Effects of cytokines on CD20 antigen expression on tumor cells from patients with chronic lymphocytic leukemia
-
DOI 10.1016/S0145-2126(99)00206-4, PII S0145212699002064
-
Sivaraman S, Venugopal P, Ranganathan R, et al. Effect of interferon-alpha on CD20 antigen expression of B-cell chronic lymphocytic leukemia. Cytokines Cell Mol Ther. 2000;6(2):81-87. (Pubitemid 30227241)
-
(2000)
Leukemia Research
, vol.24
, Issue.5
, pp. 411-415
-
-
Venugopal, P.1
Sivaraman, S.2
Huang, X.-K.3
Nayini, J.4
Gregory, S.A.5
Preisler, H.D.6
-
23
-
-
0031656896
-
Interferon-alpha and granulocyte-macrophage colony-stimulating factor differentiate peripheral blood monocytes into potent antigen-presenting cells
-
Paquette RL, Hsu NC, Kiertscher SM, et al. Interferon-alpha and granulocyte-macrophage colony-stimulating factor differentiate peripheral blood monocytes into potent antigen-presenting cells. J Leukoc Biol. 1998;64(3):358-367. (Pubitemid 28409243)
-
(1998)
Journal of Leukocyte Biology
, vol.64
, Issue.3
, pp. 358-367
-
-
Paquette, R.L.1
Hsu, N.C.2
Kiertscher, S.M.3
Park, A.N.4
Tran, L.5
Roth, M.D.6
Glaspy, J.A.7
-
24
-
-
0021933051
-
Human interferon alpha in malignant lymphoma and Hodgkin's disease: Results of the American Cancer Society trial
-
Horning SJ, Merigan TC, Krown SE, et al. Human interferon alpha in malignant lymphoma and Hodgkin's disease: results of the American Cancer Society trial. Cancer. 1985;56(6):1305-1310.
-
(1985)
Cancer
, vol.56
, Issue.6
, pp. 1305-1310
-
-
Horning, S.J.1
Merigan, T.C.2
Krown, S.E.3
-
25
-
-
0025937962
-
Interferon alpha in lymphoma
-
Rohatiner AZ. Interferon alpha in lymphoma. Br J Haematol. 1991;79(suppl 1):26-29.
-
(1991)
Br J Haematol
, vol.79
, Issue.SUPPL. 1
, pp. 26-29
-
-
Rohatiner, A.Z.1
-
26
-
-
20244362381
-
Meta-analysis to evaluate the role of interferon in follicular lymphoma
-
DOI 10.1200/JCO.2005.06.146
-
Rohatiner AZ, Gregory WM, Peterson B, et al. Meta-analysis to evaluate the role of interferon in follicular lymphoma. J Clin Oncol. 2005;23(10):2215-2223. (Pubitemid 46218713)
-
(2005)
Journal of Clinical Oncology
, vol.23
, Issue.10
, pp. 2215-2223
-
-
Rohatiner, A.Z.S.1
Gregory, W.M.2
Peterson, B.3
Borden, E.4
Solal-Celigny, P.5
Hagenbeek, A.6
Fisher, R.I.7
Unterhalt, M.8
Arranz, R.9
Chisesi, T.10
Aviles, A.11
Lister, T.A.12
-
27
-
-
0033993704
-
Activity of interferon-alpha in relapsed patients with diffuse large B-cell and peripheral T-cell non-Hodgkin's lymphoma
-
DOI 10.1023/A:1008384506227
-
Armitage JO, Coiffier B. Activity of interferonalpha in relapsed patients with diffuse large B-cell and peripheral T-cell non-Hodgkin's lymphoma. Ann Oncol. 2000;11(3):359-361. (Pubitemid 30214677)
-
(2000)
Annals of Oncology
, vol.11
, Issue.3
, pp. 359-361
-
-
Armitage, J.O.1
Coiffier, B.2
-
29
-
-
0033911321
-
Combination immunotherapy of relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma with rituximab and interferon-alpha-2a
-
Davis TA, Maloney DG, Grillo-Lopez AJ, et al. Combination immunotherapy of relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma with rituximab and interferon-alpha-2a. Clin Cancer Res. 2000;6(7):2644-2652.
-
(2000)
Clin Cancer Res
, vol.6
, Issue.7
, pp. 2644-2652
-
-
Davis, T.A.1
Maloney, D.G.2
Grillo-Lopez, A.J.3
-
30
-
-
38549100096
-
Long-term molecular remissions in patients with indolent lymphoma treated with rituximab as a single agent or in combination with interferon alpha-2a: A randomized phase II study from the Nordic Lymphoma Group
-
DOI 10.1080/10428190701704647, PII 789687799
-
Kimby E, Jurlander J, Geisler C, et al. Long-term molecular remissions in patients with indolent lymphoma treated with rituximab as a single agent or in combination with interferon alpha-2a: a randomized phase II study from the Nordic Lymphoma Group. Leuk Lymphoma. 2008;49(1):102-112. (Pubitemid 351146889)
-
(2008)
Leukemia and Lymphoma
, vol.49
, Issue.1
, pp. 102-112
-
-
Kimby, E.1
Jurlander, J.2
Geisler, C.3
Hagberg, H.4
Holte, H.5
Lehtinen, T.6
Ostenstad, B.7
Hansen, M.8
Osterborg, A.9
Linden, O.10
Sundstrom, C.11
-
31
-
-
0035134688
-
Interferon in oncological practice: Review of interferon biology, clinical applications, and toxicities
-
DOI 10.1634/theoncologist.6-1-34
-
Jonasch E, Haluska FG. Interferon in oncological practice: review of interferon biology, clinical applications, and toxicities. Oncologist. 2001;6(1):34-55. (Pubitemid 32155814)
-
(2001)
Oncologist
, vol.6
, Issue.1
, pp. 34-55
-
-
Jonasch, E.1
Haluska, F.G.2
-
32
-
-
0038485519
-
Adenovirus-mediated gene transfer of interferon alpha improves dimethylnitrosamine-induced liver cirrhosis in rat model
-
DOI 10.1038/sj.gt.3301949
-
Suzuki K, Aoki K, Ohnami S, et al. Adenovirus-mediated gene transfer of interferon alpha improves dimethylnitrosamine-induced liver cirrhosis in rat model. Gene Ther. 2003;10(9):765-773. (Pubitemid 36621820)
-
(2003)
Gene Therapy
, vol.10
, Issue.9
, pp. 765-773
-
-
Suzuki, K.1
Aoki, K.2
Ohnami, S.3
Yoshida, K.4
Kazui, T.5
Kato, N.6
Inoue, K.7
Kohara, M.8
Yoshida, T.9
-
33
-
-
7044245847
-
Systemic remission of non-Hodgkin's lymphoma after intralesional interferon alpha-2b to bilateral conjunctival lymphomas
-
Ross JJ, Tu KL, Damato BE. Systemic remission of non-Hodgkin's lymphoma after intralesional interferon alpha-2b to bilateral conjunctival lymphomas. Am J Ophthalmol. 2004;138(4):672-673.
-
(2004)
Am J Ophthalmol
, vol.138
, Issue.4
, pp. 672-673
-
-
Ross, J.J.1
Tu, K.L.2
Damato, B.E.3
-
34
-
-
33744906556
-
Intra-lesional low-dose interferon alpha2a therapy for primary cutaneous marginal zone B-cell lymphoma
-
DOI 10.1080/10428190500399698, PII N1451122466
-
Cozzio A, Kempf W, Schmid-Meyer R, et al. Intralesional low-dose interferon alpha2a therapy for primary cutaneous marginal zone B-cell lymphoma. Leuk Lymphoma. 2006;47(5):865-869. (Pubitemid 43840642)
-
(2006)
Leukemia and Lymphoma
, vol.47
, Issue.5
, pp. 865-869
-
-
Cozzio, A.1
Kempf, W.2
Schmid-Meyer, R.3
Gilliet, M.4
Michaelis, S.5
Scharer, L.6
Burg, G.7
Dummer, R.8
-
35
-
-
33747621382
-
Adenovirus delivery provides extended interferon-alpha exposure and augments treatment of metastatic carcinoma
-
DOI 10.1038/sj.cgt.7700942, PII 7700942
-
Brin E, Atencio I, Helmich BK, Maneval D, Laface D. Adenovirus delivery provides extended interferon-alpha exposure and augments treatment of metastatic carcinoma. Cancer Gene Ther. 2006;13(7):664-675. (Pubitemid 44264471)
-
(2006)
Cancer Gene Therapy
, vol.13
, Issue.7
, pp. 664-675
-
-
Brin, E.1
Atencio, I.2
Helmich, B.K.3
Maneval, D.4
Laface, D.5
-
36
-
-
52949148222
-
Tumor-targeted interferon-alpha delivery by Tie2-expressing monocytes inhibits tumor growth and metastasis
-
De Palma M, Mazzieri R, Politi LS, et al. Tumor-targeted interferon-alpha delivery by Tie2-expressing monocytes inhibits tumor growth and metastasis. Cancer Cell. 2008;14(4):299-311.
-
(2008)
Cancer Cell
, vol.14
, Issue.4
, pp. 299-311
-
-
De Palma, M.1
Mazzieri, R.2
Politi, L.S.3
-
38
-
-
38449120108
-
Targeting IFN-alpha to B cell lymphoma by a tumor-specific antibody elicits potent antitumor activities
-
Huang TH, Chintalacharuvu KR, Morrison SL. Targeting IFN-alpha to B cell lymphoma by a tumor-specific antibody elicits potent antitumor activities. J Immunol. 2007;179(10):6881-6888.
-
(2007)
J Immunol
, vol.179
, Issue.10
, pp. 6881-6888
-
-
Huang, T.H.1
Chintalacharuvu, K.R.2
Morrison, S.L.3
-
39
-
-
67651163872
-
Intratumoral but not systemic delivery of CpG oligodeoxynucleotide augments the efficacy of anti-CD20 monoclonal antibody therapy against B cell lymphoma
-
Betting DJ, Yamada RE, Kafi K, Said J, van Rooijen N, Timmerman JM. Intratumoral but not systemic delivery of CpG oligodeoxynucleotide augments the efficacy of anti-CD20 monoclonal antibody therapy against B cell lymphoma. J Immunother. 2009;32(6):622-631.
-
(2009)
J Immunother
, vol.32
, Issue.6
, pp. 622-631
-
-
Betting, D.J.1
Yamada, R.E.2
Kafi, K.3
Said, J.4
Van Rooijen, N.5
Timmerman, J.M.6
-
40
-
-
70349271119
-
Inhibitors of MyD88-dependent proinflammatory cytokine production identified utilizing a novel RNA interference screening approach
-
Cho JS, Kim YC, Morrison SL. Inhibitors of MyD88-dependent proinflammatory cytokine production identified utilizing a novel RNA interference screening approach. PLoS One. 2009;4(9):e7029.
-
(2009)
PLoS One
, vol.4
, Issue.9
-
-
Cho, J.S.1
Kim, Y.C.2
Morrison, S.L.3
-
41
-
-
69449105856
-
Recombinant anti-CD20 antibody fragments for smallanimal PET imaging of B-cell lymphomas
-
Olafsen T, Betting D, Kenanova VE, et al. Recombinant anti-CD20 antibody fragments for smallanimal PET imaging of B-cell lymphomas. J Nucl Med. 2009;50(9):1500-1508.
-
(2009)
J Nucl Med
, vol.50
, Issue.9
, pp. 1500-1508
-
-
Olafsen, T.1
Betting, D.2
Kenanova, V.E.3
-
42
-
-
33745912405
-
A time- And cost-efficient system for high-level protein production in mammalian cells
-
DOI 10.1107/S0907444906029799
-
Aricescu AR, Lu W, Jones EY. A time- and cost-efficient system for high-level protein production in mammalian cells. Acta Crystallogr D Biol Crystallogr. 2006;62(pt 10):1243-1250. (Pubitemid 44526216)
-
(2006)
Acta Crystallographica Section D: Biological Crystallography
, vol.62
, Issue.10
, pp. 1243-1250
-
-
Aricescu, A.R.1
Lu, W.2
Jones, E.Y.3
-
43
-
-
0024354304
-
Determination of subcutaneous tumor size in athymic (nude) mice
-
Tomayko MM, Reynolds CP. Determination of subcutaneous tumor size in athymic (nude) mice. Cancer Chemother Pharmacol. 1989;24(3):148-154.
-
(1989)
Cancer Chemother Pharmacol
, vol.24
, Issue.3
, pp. 148-154
-
-
Tomayko, M.M.1
Reynolds, C.P.2
-
44
-
-
0028057250
-
Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20
-
Reff ME, Carner K, Chambers KS, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood. 1994;83(2):435-445. (Pubitemid 24030569)
-
(1994)
Blood
, vol.83
, Issue.2
, pp. 435-445
-
-
Reff, M.E.1
Carner, K.2
Chambers, K.S.3
Chinn, P.C.4
Leonard, J.E.5
Raab, R.6
Newman, R.A.7
Hanna, N.8
Anderson, D.R.9
-
45
-
-
0023035950
-
Synergistic antitumor effect of interferon and anti-idiotype monoclonal antibody in murine lymphoma
-
Basham TY, Kaminski MS, Kitamura K, Levy R, Merigan TC. Synergistic antitumor effect of interferon and anti-idiotype monoclonal antibody in murine lymphoma. J Immunol. 1986;137(9):3019-3024. (Pubitemid 17177817)
-
(1986)
Journal of Immunology
, vol.137
, Issue.9
, pp. 3019-3024
-
-
Basham, T.Y.1
Kaminski, M.S.2
Kitamura, K.3
-
46
-
-
3042737572
-
A new multi-parameter flow cytometric assay for monitoring lymphoma growth and spread in a pre-clinical murine model for human lymphoma
-
Neeson P, Paterson Y. A new multi-parameter flow cytometric assay for monitoring lymphoma growth and spread in a pre-clinical murine model for human lymphoma. Cytometry A. 2004;60(1):8-20. (Pubitemid 38859197)
-
(2004)
Cytometry Part a
, vol.60
, Issue.1
, pp. 8-20
-
-
Neeson, P.1
Paterson, Y.2
-
47
-
-
0034660092
-
Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis
-
Golay J, Zaffaroni L, Vaccari T, et al. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. Blood. 2000;95(12):3900-3908. (Pubitemid 30412866)
-
(2000)
Blood
, vol.95
, Issue.12
, pp. 3900-3908
-
-
Golay, J.1
Zaffaroni, L.2
Vaccari, T.3
Lazzari, M.4
Borleri, G.-M.5
Bernasconi, S.6
Tedesco, F.7
Rambaldi, A.8
Introna, M.9
-
48
-
-
0032030699
-
Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies
-
Shan D, Ledbetter JA, Press OW. Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies. Blood. 1998;91(5):1644-1652. (Pubitemid 28110329)
-
(1998)
Blood
, vol.91
, Issue.5
, pp. 1644-1652
-
-
Shan, D.1
Ledbetter, J.A.2
Press, O.W.3
-
49
-
-
70449729725
-
CD20-targeted tetrameric interferon-{alpha}, a novel and potent immunocytokine for the therapy of B-cell lymphomas
-
Rossi EA, Goldenberg DM, Cardillo TM, Stein R, Chang CH. CD20-targeted tetrameric interferon-{alpha}, a novel and potent immunocytokine for the therapy of B-cell lymphomas. Blood. 2009;114(18):3864-3871.
-
(2009)
Blood
, vol.114
, Issue.18
, pp. 3864-3871
-
-
Rossi, E.A.1
Goldenberg, D.M.2
Cardillo, T.M.3
Stein, R.4
Chang, C.H.5
-
50
-
-
33847014608
-
Development of rituximab-resistant lymphoma clones with altered cell signaling and cross-resistance to chemotherapy
-
DOI 10.1158/0008-5472.CAN-06-2184
-
Jazirehi AR, Vega MI, Bonavida B. Development of rituximab-resistant lymphoma clones with altered cell signaling and cross-resistance to chemotherapy. Cancer Res. 2007;67(3):1270-1281. (Pubitemid 46270787)
-
(2007)
Cancer Research
, vol.67
, Issue.3
, pp. 1270-1281
-
-
Jazirehi, A.R.1
Vega, M.I.2
Bonavida, B.3
|